Rajesh Magow’s refusal to put a number on it is subtly telling. The co-founder and group CEO repeatedly refused to disclose revenue estimates related to the company’s new GenAI assistant when MakeMyTrip released the updated version of Myra last week.
He stated, “We are not putting a number right now and telling our teams: ‘Okay, here’s the target on this interface,'” at the briefing. That kind of restraint seems almost archaic in a market that has been trained to demand quarterly clarity.
| Company | MakeMyTrip |
| Founded | 2000 |
| Headquarters | Gurugram, Haryana, India |
| Co-Founder & Group CEO | Rajesh Magow |
| Group CTO | Sanjay Mohan |
| Listed On | Nasdaq: MMYT |
| Q1 FY26 Adjusted Operating Profit | $47.3 million (up 21% YoY) |
| Latest Product | GenAI Trip Planning Assistant — Myra (Beta) |
| Languages Supported (Beta) | English, Hindi (more Indian languages planned) |
| Input Modes | Text, voice, image, video |
| Travel Categories Covered | Flights, hotels, holidays, ground transport, visas, forex |
However, the product itself is anything but restrained. Myra, a fairly traditional AI agent that has lived inside MakeMyTrip’s app, can now converse back-and-forth in Hindi or English via voice or text, guiding a traveler from a vague vacation fantasy to a confirmed booking. When you ask it for a three-star hotel in Udaipur for less than ₹3,500 in Hindi, it does more than simply provide a list. It bargains with you for the trip. It makes changes to itineraries. Post-sale inquiries are handled by it. On paper, the transition from a suggestion engine to something more akin to a travel agent on call is substantial.
However, the story about who this is actually for is more fascinating. Although there are about 900 million internet users in India, very few of them actually conduct online travel transactions. Language, comfort, and the minor embarrassments of typing English into a search bar when English is not your primary language have been the main points of contention rather than smartphones or data plans.

Here, Magow uses straightforward framing. He claims that the company’s target market is the “Bharat heartland,” which has “shied away so far.”
This might be the right wager at the right moment. Additionally, conversational AI in regional languages may still have more flaws than the launch event revealed. Fluency claims often surpass actual fluency, as anyone who has seen a voice assistant mispronounce a place name in Tamil or stumble over a code-switched Hindi sentence will attest. Sanjay Mohan, the group CTO, gives the impression that the business is aware of this. He cited Hemingway’s famous statement that change occurs “gradually, then suddenly,” and he predicted that GenAI adoption would probably follow that trajectory. The truth is that no one is certain when the curve will bend, only that it will.
The wider posture is what lends some weight to the move. MakeMyTrip is expanding, profitable, and unthreatened. In the quarter that ended in June, adjusted operating profit increased 21% year over year to $47.3 million. The business might have failed. Rather, it is handling GenAI in the same manner as infrastructure firms handle fiber: invest now, worry about the meter later. “If you don’t catch the right trend and if you’re not a front runner,” Mohan stated, “there’s a larger risk.” It’s difficult to miss the subtext: travel aggregators around the world are keeping an eye on the same disruption clock, and arriving early is less expensive than being late.
Both executives dismissed the inevitable question about jobs with the typical upskilling response. It’s a different matter entirely whether that holds true over the next five years. As you watch this unfold, the smaller image that sticks in your mind is of a first-time traveler in a Tier-3 town asking Myra, in their native tongue, where to take the kids in August. MakeMyTrip will have accomplished something that its rivals have only discussed if that discussion truly results in a reservation. If it doesn’t, the business will have costly discovered what the industry as a whole is about to discover.
London Bilingualism's content on health, medicine, and weight loss is solely meant for general educational and informational purposes. This website does not offer any diagnosis, treatment recommendations, or medical advice.
We consistently compile and disseminate the most recent information, findings, and advancements from the medical, health, and weight loss sectors. When content contains opinions, commentary, or viewpoints from professionals, industry leaders, or other people, it is published exactly as it is and reflects those people's opinions rather than London Bilingualism's editorial stance.
We strongly advise all readers to consult a qualified medical professional before acting on any medical, health, dietary, or pharmaceutical information found on this website. Since every person's health situation is different, only a qualified healthcare provider who is familiar with your medical history can offer you advice that is suitable for you.
In a similar vein, any legal, regulatory, or compliance-related information found on this platform is provided solely for informational purposes and should not be used without first obtaining independent legal counsel from a licensed attorney.
You understand and agree that London Bilingualism, its editors, contributors, and affiliated parties are not responsible for any decisions made using the information on this website.
